Clinical Trial Update: A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer [Phase 1]

View source ↗

Summary

A completed Phase I study of oral COL-3 (NSC-683551), an matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer, including lymphoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lymphoma
• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• COL-3 (COL-3)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Melanoma | Phase 1 | Status: COMPLETED